Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
Truist Securities analyst Danielle Brill reiterated a Buy rating and $110.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).The analyst comments ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)